FDA approves r4 Vasculars apheresis catheter

Kaitlyn Dmyterko | | Health Imaging | Screening
The FDA has granted 510(k) clearance to r4 Vascular’s Pherocious apheresis catheter, which includes a power-injectable contrast media for contrast-enhanced CT imaging.

In addition, the Maple Grove, Minn.-based company said the apheresis catheter has the capabilities to perform intravenous infusions and blood sampling, and is available in two sizes, 12.5F and 10.5F.

According to r4 Vascular, the Pherocious apheresis catheter is the fourth catheter in addition to the Pegasus, Zeus and DrainEx catheters, to be released by the company this year.

Kaitlyn Dmyterko

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.